CN
Search...
About Us
Group Overview
Management Team
Milestones of Chipscreen
Group Honors
Social Responsibility
Core Technologies and R&D
Core Technologies
Scientific Committee
R&D System
Drug Lifecycle Management
Pipeline
Pipelines
News & Events
Company News
Media Coverage
Notices & Announcements
Video Library
Investors
Company Announcements
Periodic Reports
Career Development
Contact Us
Contact Details
CN
EN
News & Events
Chipscreen Highlights: Stay Updated on Recent Hot Topics
Home
News & Events
Company News
Media Coverage
Notices & Announcements
Video Library
Select year
2026
2025
2024
2023
2022
Earlier
shown/page
5
5
10
15
20
2025.12.07
Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug
Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug
Full text
2025.12.05
Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award
Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award
Full text
2025.11.19
Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery
Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery
Full text
2025.11.15
Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF
Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF
Full text
2025.11.03
ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%
ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%
Full text
02
03
04
...
24
Media contact
（+86）0755-36993500
pr@juliucq.com
